Aimee O’Donohue
Bristol-Myers Squibb (United States)(US)
Publications by Year
Research Areas
Protein Degradation and Inhibitors, CAR-T cell therapy research, Ubiquitin and proteasome pathways, Peptidase Inhibition and Analysis, Cancer Cells and Metastasis
Most-Cited Works
- → Antibody Conjugation of a Chimeric BET Degrader Enables in vivo Activity(2019)185 cited
- → Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 2: Improvement of In Vitro Antiproliferation Activity and In Vivo Antitumor Efficacy(2021)161 cited
- → Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 1: Exploration of Antibody Linker, Payload Loading, and Payload Molecular Properties(2021)144 cited
- → Development of Efficient Chemistry to Generate Site-Specific Disulfide-Linked Protein– and Peptide–Payload Conjugates: Application to THIOMAB Antibody–Drug Conjugates(2017)59 cited
- → Front Cover: Antibody Conjugation of a Chimeric BET Degrader Enables in vivo Activity (ChemMedChem 1/2020)(2020)22 cited
- → Suppression of Myeloid Cell-Derived Proinflammatory Cytokines with Celmod Agents: Implications for CRS with T-Cell Engagers (TCEs)(2022)6 cited
- → Abstract 4494: A clinical candidate anti-mesothelin-MMAE antibody-drug conjugate (ADC) for therapy of mesothelin-expressing cancers(2014)1 cited